Immunologic effect and clinical impact of erythromycin in septic patients: A randomized clinical trial
Authors' conclusion
Neither the pro/anti-inflammatory imbalance nor the mortality were impacted by the addition of erythromycin to standard care in septic patients
Study context
- Population
- Critical septic patients
- Participants
- 110 patients
- Comparison
- Erythromycin added to standard care vs placebo
- Erythromycinn = 55
- Placebon = 55reference
- Primary endpoint
- Change in the TNF/IL-10 ratio
- Follow-up
- Between days 0 and 6
Methodological detailssingle-blind
- Single-blind
Primary result
As reported in the abstract
Serum TNF/IL-10 ratio, day 0 to day 6
- Erythromycin: from 0.48 [0.34-1.18] to 0.59 [0.21-1.10], no significant rise
- p = 0.86
- Placebo: from 0.65 [0.25-1.14] to 0.93 [0.24-1.88], no significant rise
- p = 0.12
Secondary outcomes
Mortality
P = 0.62
| Outcome | P value |
|---|---|
| Serum TNF/IL-10 ratio, non-survivors vs survivors · day 6Spread printed in brackets, kind not stated | P = 0.029 |
- Serum TNF/IL-10 ratio, non-survivors vs survivors: Non-survivors 0.55 (range 0.17–1.04)
- Serum TNF/IL-10 ratio, non-survivors vs survivors: Survivors 1.08 (range 0.4–2.28)
Serum Procalcitonin (PCT) and CRP
- PCT and CRP dropped considerably in the Erythromycin group; only PCT dropped in the placebo group
Original publication
Immunologic effect and clinical impact of erythromycin in septic patients: A randomized clinical trial. J Crit Care. Published 14 February 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →